NUVECTIS PHARMA INC (NVCT)

US67080T1088 - Common Stock

5.15  +0.2 (+4.04%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NVCT. NVCT was compared to 571 industry peers in the Biotechnology industry. NVCT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NVCT is valued expensive and it does not seem to be growing.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NVCT has reported negative net income.
NVCT had a negative operating cash flow in the past year.

1.2 Ratios

NVCT's Return On Assets of -111.94% is on the low side compared to the rest of the industry. NVCT is outperformed by 77.95% of its industry peers.
The Return On Equity of NVCT (-176.27%) is worse than 66.84% of its industry peers.
Industry RankSector Rank
ROA -111.94%
ROE -176.27%
ROIC N/A
ROA(3y)-134.37%
ROA(5y)N/A
ROE(3y)-206.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NVCT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

NVCT has more shares outstanding than it did 1 year ago.
NVCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of 0.56, we must say that NVCT is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of NVCT (0.56) is better than 66.31% of its industry peers.
NVCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.56
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

NVCT has a Current Ratio of 2.74. This indicates that NVCT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of NVCT (2.74) is worse than 67.90% of its industry peers.
A Quick Ratio of 2.74 indicates that NVCT has no problem at all paying its short term obligations.
NVCT has a worse Quick ratio (2.74) than 65.96% of its industry peers.
Industry RankSector Rank
Current Ratio 2.74
Quick Ratio 2.74

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 21.38% over the past year.
EPS 1Y (TTM)21.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NVCT is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.58% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y26.67%
EPS Next 2Y13.27%
EPS Next 3Y6.58%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NVCT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVCT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.27%
EPS Next 3Y6.58%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NVCT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUVECTIS PHARMA INC

NASDAQ:NVCT (11/26/2024, 8:00:02 PM)

5.15

+0.2 (+4.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap99.50M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -111.94%
ROE -176.27%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.74
Quick Ratio 2.74
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)21.38%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y26.67%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y